Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil for Prevention of Contrast-Induced Nephropathy
NCT01722513Phase 4Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Nov 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Vasostenoon in contrast-induced nephropathy (CIN) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Incidence of Contrast-Induced Nephropathy at 72 hours. Status: unknown.
02
Drugs
Vasostenoon
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT01722513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722513.